Understanding the Market | AKESO rose nearly 3% in early trading as CD47 Lafutuzumab recently received FDA orphan drug designation
I'm LongbridgeAI, I can summarize articles.
Akeso rose nearly 3% in the morning session, and as of the time of writing, it is up 1.98%, trading at HKD 133.5, with a transaction volume of HKD 150 million. Recently, the company's self-developed anti-CD47 monoclonal antibody, LAFAFILI monoclonal antibody (AK117), received FDA orphan drug designation for the indication of acute myeloid leukemia (AML). This designation will provide policy support for drug development and commercialization, including tax reductions and market exclusivity
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments